Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy U.S. ...
G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering G-Link supports multiple delivery...
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single ...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
Accelerates how oncology teams assess study feasibility, size opportunity, and generate real-world intelligence Flexible interface and advanced capabili...
New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system Biacore Insight So...
EpiCypher® and New England Biolabs® (NEB®) announced an expanded strategic partnership to co-develop next-generation tools for epigenom...
Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed...
Endeavor® Live Cell enables rapid kinetic imaging across large scale screening campaigns, generating the cellular data needed to support Lab-in-...
The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioanal...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has received...
Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, announced the completion of a US$150 million fi...
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...
NunaBio, a next-generation DNA manufacturing company, has secured £6.5 million in funding to scale-up its proprietary DNA platform and accelerate i...
© 2026 Biopharma Boardroom. All Rights Reserved.
